Patents by Inventor Claes Wadelius

Claes Wadelius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Best's macular dystrophy gene
    Publication number: 20060105364
    Abstract: Novel human and mouse DNA sequences that encode the gene CG1CE, which, when mutated, is responsible for Best's macular dystrophy, are provided. Provided are genomic CG1CE DNA as well as cDNA that encodes the CG1CE protein. Also provided is CG1CE protein encoded by the novel DNA sequences. Methods of expressing CG1CE protein in recombinant systems are provided. Also provided are diagnostic methods that detect patients having mutant CG1CE genes.
    Type: Application
    Filed: September 27, 2005
    Publication date: May 18, 2006
    Inventors: Konstantin Petrukhin, C. Caskey, Michael Metzker, Claes Wadelius
  • Best's macular dystrophy gene
    Patent number: 7005290
    Abstract: Novel human and mouse DNA sequences that encode the gene CG1CE, which, when mutated, is responsible for Best's macular dystrophy, are provided. Provided are genomic CG1CE DNA as well as cDNA that encodes the CG1CE protein. Also provided is CG1CE protein encoded by the novel DNA sequences. Methods of expressing CG1CE protein in recombinant systems are provided. Also provided are diagnostic methods that detect patients having mutant CG1CE genes.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: February 28, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Konstantin Petrukhin, C. Thomas Caskey, Michael Metzker, Claes Wadelius
  • NOS-2 and glaucoma
    Publication number: 20050255506
    Abstract: Methods of diagnosis of the presence or absence of an NOS-2-associated increased risk of glaucoma, or of a NOS-2-associated decreased risk of glaucoma, are described, in which a sample is tested for the presence of certain alleles of polymorphisms in the promoter of NOS-2, that are associated with an increased risk of glaucoma or with a decreased risk of glaucoma. Also described are methods of therapy of glaucoma, utilizing NOS-2 therapeutic agents.
    Type: Application
    Filed: February 16, 2005
    Publication date: November 17, 2005
    Applicant: Insite Vision Incorporated
    Inventor: Claes Wadelius